2020年8月4日
Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.
Japanese journal of clinical oncology
- 巻
- 50
- 号
- 8
- 開始ページ
- 948
- 終了ページ
- 952
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1093/jjco/hyaa070
- 出版者・発行元
- OXFORD UNIV PRESS
The prognosis of patients with relapsed osteosarcoma is extremely poor and the optimal treatment remains to be identified. Here, we retrospectively analysed the clinical outcomes of nine patients with relapsed osteosarcoma treated with temozolomide/etoposide. Of the two patients who received temozolomide/etoposide as palliative therapy for unresectable tumours, one remained alive with stable disease for >4 years. The remaining seven patients received temozolomide/etoposide as adjuvant therapy following resection of relapsed metastatic disease; of these, one was free from disease for 41 months. Potentially beneficial effects were observed in two of three O6-methylguanine-DNA methyltransferase protein-negative patients, whereas all five O6-methylguanine-DNA methyltransferase-positive patients experienced subsequent relapse. None of the patients experienced severe adverse effects requiring hospitalization. Temozolomide/etoposide is a feasible candidate as salvage therapy for relapsed osteosarcoma. Further studies are needed to verify the utility of O6-methylguanine-DNA methyltransferase protein expression as a biomarker for predicting the response to this treatment.
- リンク情報
- ID情報
-
- DOI : 10.1093/jjco/hyaa070
- ISSN : 0368-2811
- eISSN : 1465-3621
- PubMed ID : 32463097
- Web of Science ID : WOS:000593052300016